Trial site
Polyclinique Bordeaux Nord Aquitaine
- 21running trials
- 6closed trials
The trials here
What the 27 trials at this site are about, from their registry records.
- Conditions
- Lung cancer6 trials
- Metastatic breast cancer6 trials
- Colorectal cancer4 trials
- Triple-negative breast cancer4 trials
- Diffuse large B-cell lymphoma2 trials
- Gastric and oesophageal cancer2 trials
- Multiple myeloma2 trials
- Bladder cancer1 trial
- Brain metastases1 trial
- Childhood cancers1 trial
- Chronic kidney disease1 trial
- Liver and biliary tract cancer1 trial
- Phase
- Phase 311 trials
- Phase 28 trials
- Status
- Recruiting9 trials
- Not yet recruiting7 trials
- Completed6 trials
- Active, not recruiting5 trials
- Lead sponsor
- UNICANCER4 trials
- Fondation Franc.Cancerologie Digestive2 trials
- Hoffmann-La Roche2 trials
- Institut Curie2 trials
- Intergroupe Francophone du Myelome2 trials
- and 14 more
Running trials
Not yet recruiting
Not yet recruiting
Recruiting
Recruiting
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
Recruiting
Recruiting
Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
Recruiting
Recruiting
Active, not recruiting
Not yet recruiting
Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma
Active, not recruiting
Active, not recruiting
Active, not recruiting
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Metastatic breast cancer5 recruiting
- Triple-negative breast cancer4 recruiting
- Colorectal cancer2 recruiting
- Diffuse large B-cell lymphoma2 recruiting
- Brain metastases1 recruiting
- Childhood cancers1 recruiting
- Lung cancer1 recruiting
- Multiple myeloma1 recruiting
Closed trials
Completed
Not yet recruiting
Completed
Completed
Completed
Completed
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
Site data: ClinicalTrials.govUpdated 18 Nov 2026